[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356675-105":59,"doc-detail-356675-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","biobank-of-genetically-defined-murine-prostate-cancer-tumoroids-uncovers-oncogenic-pathways-and-drug-vulnerabilities-driven-by-pten-loss","Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss","","Establishing and characterizing a biobank of murine prostate organoids and prostate cancer tumoroids, this work models key patient-relevant mutations to study genotype-specific drug responses. Medium-throughput screening identifies targeted compounds that suppress prostate cancer growth and improve antiandrogen therapy outcomes. The study links metabolic characteristics of PCa to the PI3K/AKT pathway and highlights PTEN-loss driven oncogenic signaling. Promising therapeutic options include PI3K/AKT pathway or sirtuin targeting.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/biobank-of-genetically-defined-murine-prostate-cancer-tumoroids-uncovers-oncogenic-pathways-and-drug-vulnerabilities-driven-by-pten-loss/356675/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/biobank-of-genetically-defined-murine-prostate-cancer-tumoroids-uncovers-oncogenic-pathways-and-drug-vulnerabilities-driven-by-pten-loss/356675.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What models are created in this study, and what is their purpose?","Question",{"text":112,"@type":113},"The study establishes murine prostate organoid and tumor-derived tumoroid models carrying selected patient-relevant mutations. They are designed to reflect genotype-specific drug responses and support preclinical therapeutic testing.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which genetic alterations drive activation of cancer-related pathways?",{"text":117,"@type":113},"Deletion of Pten alone, and also in combination with Stat3 or Tp53, drives activation of cancer-related pathways in both prostate organoids and tumor-derived tumoroids.",{"name":119,"@type":110,"acceptedAnswer":120},"How were drug vulnerabilities identified, and what compounds showed activity?",{"text":121,"@type":113},"A medium-throughput drug screen identified two potent compounds: the PDPK1/AKT/FLT dual pathway inhibitor and the sirtuin inhibitor tenovin-6. Both effectively suppressed tumoroid proliferation and inhibited growth in multiple human PCa cell lines.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356675,1790194298,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Resource  \nBiobank of genetically defined murine prostate cancer tumoroids uncoversoncogenic pathways and drug vulnerabilities driven by PTEN-loss  \nAuthors  \nJessica Kalla, Thomas Dillinger, Zlata Pavlovicova,   , Stefan Kubicek, Lukas Kenner, Gerda Egger  \nCorrespondence  \n[gerda.egger@meduniwien.ac.at](gerda.egger@meduniwien.ac.at)  \nIn brief  \nKalla et al. establish and characterize abiobank of murine prostate organoidsand prostate cancer tumoroids that model key patient-relevant mutations, providing a versatile platform for drug discovery. A medium-throughput drug screen identifies targeted compounds that effectively inhibit prostate cancer growth and enhance antiandrogen therapy for future treatment development.  \n• Unique metabolic characteristics of PCa are dependent on the PI3K/AKT pathway  \n• A medium-throughput drug screen identifies PCa-specific compounds  \n• Targeting PI3K/AKT signaling or sirtuins are promising treatment options for PCa  \nKalla et al., 2026, Cell Reports Methods 6, 101370  \nApril 20, 2026 © 2026 The Authors. Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.crmeth.2026.101370](https://doi.org/10.1016/j.crmeth.2026.101370)  \nll  \nll  \nOPEN ACCESS  \nResource  \nBiobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss  \nJessica Kalla,1 Thomas Dillinger,2 Zlata Pavlovicova,2 Reema Jacob,2 Emine Atas,1,3 Katarina Miura,1 Anil Baskan,1 Kristina Dragani,1 Andreas Tiefenbacher,1 Tanja Limberger,1,4 Theresia Mair,1 Gabriel Wasinger,1 Ludovica Villanti,5 Stefan Kubicek,5 Lukas Kenner,1,3,4,6,7,8 and Gerda Egger1,2,7,9,*  \n1Department of Pathology, Medical University of Vienna, Vienna, Vienna 1090, Austria  \n2Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Vienna 1090, Austria  \n3Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Vienna 1090, Austria  \n4Centre for Biomarker Research in Medicine GmbH (CBmed), Graz, Styria 8010, Austria  \n5CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Vienna 1090, Austria  \n6Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Vienna 1210, Austria  \n7Comprehensive Cancer Center, Medical University of Vienna, Vienna, Vienna 1090, Austria  \n8Department of Molecular Biology, Ume˚a University, 901 87 Ume˚a, V¨asterbottens, Sweden  \n9Lead contact  \n*Correspondence: [gerda.egger@meduniwien.ac.at](gerda.egger@meduniwien.ac.at)[ ](gerda.egger@meduniwien.ac.at)[https://doi.org/10.1016/j.crmeth.2026.101370](https://doi.org/10.1016/j.crmeth.2026.101370)  \nMOTIVATION Patient-derived organoid and tumoroid models have proven invaluable for cancer research, enhancing our understanding of tumorigenesis and enabling the testing of therapeutics for personalized treatment. In case of prostate cancer, long-term cultivation of primary tumors has been less successful and thus fewer models are available. Therefore, we developed organoid and tumoroid models originating from murine prostate tissues and tumors of transgenic mice, harboring selected patient-relevant mutations, to study genotype-specific drug responses. These models are readily genetically manipulated in vitro and can be cultured for extended passages.  \nSUMMARY  \nProstate cancer (PCa) is the second most common cancer in men and shows high inter-and intra-patient heterogeneity. Consequently, treatment options are limited and there is a lack of representative preclinical models. Here, we establish a comprehensive biobank of murine organoids and tumoroids that reflect common patient mutations. We demonstrate that the deletion of Pten alone, or in combination with Stat3, or Tp53, drives the activation of cancer-related pathways in both prostate organoids and tumor-derived tumoroids. A medium-throughput drug screen identified two potent compounds, the PDPK1/AKT/FLT dual pathway inhibitor and the sirtuin inhibitor tenovin-6, which ef","cbCaives1aCMwHWZ","https://ap.wps.com/l/cbCaives1aCMwHWZ","pdf",10948741,23,"English","# Motivation\n## Summary\n# Introduction\n## Figure 1","[{\"question\":\"What models are created in this study, and what is their purpose?\",\"answer\":\"The study establishes murine prostate organoid and tumor-derived tumoroid models carrying selected patient-relevant mutations. They are designed to reflect genotype-specific drug responses and support preclinical therapeutic testing.\"},{\"question\":\"Which genetic alterations drive activation of cancer-related pathways?\",\"answer\":\"Deletion of Pten alone, and also in combination with Stat3 or Tp53, drives activation of cancer-related pathways in both prostate organoids and tumor-derived tumoroids.\"},{\"question\":\"How were drug vulnerabilities identified, and what compounds showed activity?\",\"answer\":\"A medium-throughput drug screen identified two potent compounds: the PDPK1/AKT/FLT dual pathway inhibitor and the sirtuin inhibitor tenovin-6. Both effectively suppressed tumoroid proliferation and inhibited growth in multiple human PCa cell lines.\"}]","Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss | PDF",1790126754,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2cfe0ce3c563d1a79bbd17e2e348c61.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/850a1a9131e922529f6006b8e6201041.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5256efa253d5a015041291ef41b0c73b.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18725f11a0a6e3f7b804d7a2c800156e.webp",980,1272]